Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
November-2017 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2017 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells

  • Authors:
    • Hui‑Hui Zhang
    • Bo Huang
    • You‑Han Cao
    • Qing Li
    • Han‑Feng Xu
  • View Affiliations / Copyright

    Affiliations: Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
  • Pages: 5652-5656
    |
    Published online on: August 31, 2017
       https://doi.org/10.3892/ol.2017.6853
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Chemotherapeutic insensitivity is one of key obstacles to effectively treating muscle invasive bladder cancer. 5‑Aza‑2'‑deoxycytidine (5‑Aza‑CdR) has been identified as a tumor suppressive agent in various types of cancer. The aim of the present study was to identify the effects of 5‑Aza‑CdR on the mitomycin‑C (MMC) chemosensitivity of T24 bladder cancer cells and investigate the underlying mechanisms. T24 cells were treated with a combination of MMC and 5‑Aza‑CdR at various concentrations. The rates of proliferation and apoptosis were assessed by an MTT assay and flow cytometry, respectively. The expression of drug resistance‑associated proteins, including P‑glycoprotein (P‑gp) and multidrug resistance‑associated protein 1 (MRP1), and autophagy‑associated proteins, including beclin 1, nucleoporin 62 (p62) and autophagy protein 5 (ATG5) were detected with western blotting. Treatment with 5‑Aza‑CdR significantly promoted the MMC chemosensitivity of T24 cells. The proliferation of T24 cells was significantly inhibited with increasing 5‑Aza‑CdR concentration, whereas apoptosis was significantly increased. This was associated with the decreased expression of P‑gp, MRP1, beclin 1, p62 and ATG5. In conclusion, 5‑Aza‑CdR enhanced MMC chemosensitivity in bladder cancer T24 cells, which may be caused by the suppression of drug resistance‑ and autophagy‑associated proteins.

Introduction

Bladder cancer ranks 13th in the causes for cancer-associated mortality worldwide and is the most common type of urological cancer in China (1). Muscle-invasive bladder cancer constitutes ~30% of newly diagnosed cases of bladder cancer (2). Approximately 10% of non-invasive bladder cancer cases eventually progress to invasive cancer following the transurethral resection of the bladder tumor (3). Compared with non-invasive bladder cancer, patients with invasive disease have a poor prognosis, with a 5-year survival rate of 50% (4). Systemic chemotherapy remains the major therapeutic option for muscle-invasive bladder cancer in neoadjuvant and adjuvant settings, as well as for metastatic disease. Although it often leads to an initial therapeutic success in patients with metastatic bladder cancer, 60–70% of responding patients relapse within the first year of treatment, with a median survival time of 12–14 months (5). This limited efficacy appears to be largely associated with drug resistance of the tumor during treatment. Therefore, there is an urgent requirement to develop chemosensitization strategies.

Mitomycin-C (MMC) is widely used as a chemotherapeutic drug in the treatment of bladder cancer. However, only a limited number of patients were microscopically free of tumor cells following MMC treatment. The development of resistance to MCC is a major concern in bladder cancer therapy, and the mechanism remains largely unclear. Several methods have been demonstrated to increase the anticancer efficacy of MMC therapy in bladder cancer (6,7). In our previous study, it was revealed that as a DNA methyltransferase inhibitor, 5-Aza-2′-deoxycitidine (5-Aza-CdR) could inhibit the proliferation, migration and invasion of the T24 bladder cancer cell line (8). However, whether 5-Aza-CdR could affect the chemosensitivity of T24 cells was not studied. Therefore, the present study aimed to investigate the effects of 5-Aza-CdR on the MMC chemosensitivity of bladder cancer T24 cells. The underlying mechanisms were also investigated.

Materials and methods

Cell culture and chemicals

MMC was purchased from the Zhejiang Haizheng Group Co., Ltd. (Taizhou, China). It was dissolved in physiological saline to a concentration of 0.01 mg/ml, and then stored until use at −4°C. 5-Aza-CdR was purchased from Sigma-Aldrich (Merck KGaA; Darmstadt, Germany). It was dissolved in physiological saline to a concentration of 0.25, 1 and 10 µmol/l, and then stored until use at −20°C, protected from light.

T24 human bladder cancer cells were obtained from Beijing Dingguo Changsheng Biotechnology Co., Ltd. (Beijing, China). The cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) with high glucose (4,500 mg/l), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cell culture was conducted with 5% CO2 at 37°C.

T24 cells were harvested in the exponential phase. Cells were seeded in 96-well plates at a density of 2×104 cells per well. Following incubation overnight in the previously specified conditions, the cells were treated with 0.01 mg/ml MMC and 5-Aza-CdR at different concentrations (including 0, 0.25, 1 and 10 µmol/l). T24 cells without MMC and 5-Aza-CdR served as a control. At 48 h, the cells were obtained for subsequent experiments.

MTT assay

Cells were treated with 20 µl MTT dye (Sigma-Aldrich; Merck KGaA) and incubated at 37°C for 4 h. The supernatant was then removed, and 100 µl of dimethylsulfoxide was added to every well to dissolve the formazan product. The absorbance was recorded at a wavelength of 570 nm using a microplate reader (Bio-Rad Laboratories, Inc.). The following calculation was used: Cellular inhibition rate, % = (1-treated group absorbance/control group absorbance) ×100.

Flow cytometric analysis

The cells were washed twice with PBS, harvested with pancreatin and centrifugated (164.3 × g, 5 min) at room temperature, and resuspended. The samples were incubated with 5 µl Annexin V-fluorescein isothiocyanate and 5 µl propidium iodide for exactly 5 min at room temperature in the dark and then measured on a FACS Vantage Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Western blotting

The cells were lysed with lysis buffer (ProMab Biotechnologies, Inc., Richmond, CA, USA). The total protein concentration was quantified by a bicinchoninic acid protein assay. Appropriate amounts of protein (20–40 µg per well) were separated with 10% SDS-PAGE. The proteins were then transferred to a polyvinylidene difluoride membrane. The membranes were blocked at 37°C for 3 h in a blocking solution consisting of 5% nonfat milk and TBS with 0.1% Tween-20. The primary antibodies, including mouse anti-P-gp (cat. no. ab80594; dilution, 1:1,000), mouse anti-MRP1 (cat. no. ab24102; dilution, 1:1,000), rabbit anti-beclin 1 (cat. no. ab62557; dilution, 1:1,000), mouse anti-p62 (cat. no. ab56416; dilution, 1:1,000), rabbit anti-ATG5 (cat. no. ab108327; dilution, 1:1,000) and mouse anti-GAPDH (cat. no. ab8245; dilution, 1:1,000) (all from Abcam, Cambridge, UK) were incubated overnight with the membrane at 4°C, followed by corresponding horseradish peroxidase-conjugated secondary antibodies goat anti-rabbit immunoglobulin (Ig)G/horse radish peroxidase (HRP) (cat. no. ab6721; dilution, 1:2,000) and goat anti-mouse IgG/HRP (cat. no. ab6789; dilution, 1:2,000) (all from Abcam) at room temperature for 1 h. Immunoreactive bands were detected using an Enhanced Chemiluminescence-plus kit (GE Healthcare, Chicago, IL, USA) according to the manufacturer's protocol. The chemiluminescence was analyzed using ChemiDoc XRS system with Image Lab Software version 6.0 (Bio-Rad Laboratories, Inc., Hercules, CA). The levels of the target protein were presented as the relative density vs. GAPDH.

Statistical analysis

SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data are presented as the mean ± standard deviation. The significance of the data was determined by Student's t-test and one-way analysis of variance. The post hoc test was performed using Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of 5-Aza-CdR on MMC-induced proliferation inhibition in T24 cells

To investigate the effects of 5-Aza-CdR treatment, an MTT assay was performed subsequent to treating T24 cells with different concentrations of 5-Aza-CdR (0, 0.25, 1 and 10 µmol/l) and MMC (0.01 mg/ml). 5-Aza-CdR enhanced MMC-induced proliferation inhibition in T24 cells (Fig. 1). The rate of T24 cell growth inhibition was 1.63±0.01 with MMC only, and 5.0±0.04, 15.50±0.06 and 27.16±0.11%, with 0.025, 1 or 10 µmol/l 5-Aza-CdR, respectively; growth inhibition was thus induced in a dose-dependent manner by 5-Aza-CdR (P<0.05).

Figure 1.

Effects of 5-Aza-CdR on MMC-induced growth inhibition in T24 cells. A reduced extent of cell proliferation was observed with increasing 5-Aza-CdR treatment. The data are presented as the mean ± standard deviation (n=3). *P<0.05 vs. control. MMC, mitomycin-C; 5-Aza-CdR, 5-Aza-2′-deoxycitidine.

Effects of 5-Aza-CdR on MMC-induced apoptosis in T24 cells

To determine whether 5-Aza-CdR could enhance MMC-induced apoptosis in T24 cells, flow cytometry was performed to identify the apoptotic rate of cells. The apoptotic rate increased in a 5-Aza-CdR-dose-dependent manner, including early and late apoptotic cell death (P<0.05; Fig. 2). In the control group, 3.23±0.08% of cells underwent apoptosis, whereas 4.85±0.04, 8.81±0.06, 21.14±0.05 and 38.17±0.07% of cells underwent apoptosis in the 0, 0.25, 1 and 10 µmol/l 5-Aza-CdR groups, respectively.

Figure 2.

Effects of 5-Aza-CdR on MMC-induced apoptosis in T24 cells. An increased rate of apoptosis was observed with increasing 5-Aza-CdR treatment. The experiments were conducted in triplicate. MMC, mitomycin-C; 5-Aza-CdR, 5-Aza-2′-deoxycitidine; FITC, fluorescein isothiocyanate.

Effects of 5-Aza-CdR on the expression of chemoresistance-associated proteins in T24 cells

To elucidate the potential mechanism for 5-Aza-CdR-mediated chemosensitivity alterations, western blot analysis was performed to examine the effects on P-gp and MRP1 expression. The results demonstrated that with increasing 5-Aza-CdR, the expression levels of P-gp and MRP1 were significantly decreased (P<0.05; Fig. 3).

Figure 3.

Western blot analysis of P-gp and MRP1 protein in T24 cells. (A) P-gp and MRP1 in T24 cells was measured by western blotting. 1 is the control, 2 MMC only, 3 MMC + 0.25 µmol/l, 4 MMC + 1 µmol/l and 5 MMC + 10 µmol/l 5-Aza-2′ deoxycitidine. GAPDH was used as an internal control. (B) The relative protein levels, normalized to GAPDH. P-gp and MRP1 expression were decreased with increasing 5-Aza-CdR treatment. The data are presented as the mean ± standard deviation (n=3). *P<0.05 vs. control. P-gp, P-glycoprotein; MRP1, multidrug resistance-associated protein 1; MMC, mitomycin-C; 5-Aza-CdR, 5-Aza-2′-deoxycitidine.

Effects of 5-Aza-CdR on the expression of autophagy-associated proteins in T24 cells

The expression level of the autophagy-associated proteins beclin 1, p62 and ATG5 was determined with western blot analysis. Data revealed that with increasing 5-Aza-CdR concentration, the expression levels of beclin 1, p62 and ATG5 were all significantly decreased (P<0.05; Fig. 4).

Figure 4.

Western blotting analysis of the expression of beclin 1, p62 and ATG5 protein in T24 cells. (A) Beclin 1, p62 and ATG5 expression levels in T24 cells were measured by western blotting. 1 is the control, 2 MMC only, 3 MMC + 0.25 µmol/l, 4 MMC + 1 µmol/l and 5 MMC + 10 µmol/l 5-Aza-2′ deoxycitidine. GAPDH was used as an internal control. (B) The relative protein levels, normalized to GAPDH. Beclin 1, p62 and ATG5 expression levels were decreased with increasing 5-Aza-CdR treatment. The data are presented as the mean ± standard deviation (n=3). *P<0.05 vs. control. p62, nucleoporin 62; ATG5, autophagy 5; MMC, mitomycin-C; 5-Aza-CdR, 5-Aza-2′-deoxycitidine.

Discussion

Resistance to chemotherapeutic drugs is an important reason for clinical chemotherapy failure in bladder cancer. In the present study, it was identified that 5-Aza-CdR may enhance the MMC sensitivity of T24 bladder cancer cells. The apoptosis of T24 cells was significantly promoted by combined treatment with MMC and 5-Aza-CdR, compared with those treated by MMC alone. Furthermore, with increasing 5-Aza-CdR concentrations, the cellular inhibition rates increased in a dose-dependent manner. This data indicated that 5-Aza-CdR serves a role in the enhancement of MMC chemosensitivity of bladder cancer T24 cells.

To investigate the mechanism of 5-Aza-CdR in the chemosensitivity of bladder cancer T24 cells, western blotting was used to detect the expression of P-gp and MRP1 protein, which are associated with chemotherapeutic resistance. The data revealed that the expression levels of P-gp and MRP1 protein in T24 cells following treatment with MMC were significantly decreased in a dose-dependent manner with increasing 5-Aza-CdR concentration. P-gp and MRP1 protein belong to a family of ATP-dependent efflux transporters termed the ATP-binding cassette (ABC) family of membrane transport proteins (9). Members of the ABC transporter family have the capacity to efflux small molecules, causing drug accumulation in the cell (including the accumulation of anticancer drugs) to decrease, and thus contribute to drug resistance (10). The clinical significance of P-gp and MRP1 in drug resistance is supported by evidence that their expression indicates an adverse prognosis in patients with a range of types of cancer (11,12). Yang et al (13) demonstrated that Nsc23925 could prevent the development of paclitaxel resistance by inhibiting the expression of P-gp and enhancing apoptosis. Therefore, it was concluded from the data of the present study that 5-Aza-CdR enhances MMC chemosensitivity of T24 cells by suppressing P-gp and MRP1 expression.

Based on this result, studying the mechanism for the effect of 5-Aza-CdR on the chemosensitivity of T24 bladder cancer cells may yield clinical value. The expression levels of beclin 1, p62 and ATG5 protein were then detected, which were associated with autophagy. It was demonstrated that the expression levels of beclin 1, p62 and ATG5 protein in T24 cells were decreased in a dose-dependent manner following treatment with MMC and increasing 5-Aza-CdR concentrations. Beclin 1, p62 and ATG5 are considered as the key regulators of autophagic cell death (14–16). Autophagy is a lysosome-dependent self-digesting system primarily responsible for the removal and recycling of long-lived proteins, and damaged or obsolete intracellular organelles, in order to maintain cell homeostasis (17). The exact role of autophagy in cancer remains controversial. A number of studies provide evidence that autophagy suppresses tumorigenesis (18,19), whereas other studies propose that autophagy is associated with tumor development and protects tumor cells from apoptosis (20,21). In addition, a role for autophagy in the chemosensitivity of cancer cells has been identified; Wu et al (22) reported that autophagy may facilitate the resistance of lung adenocarcinoma cells to cisplatin treatment by the activation of the AMP-activated protein kinase/mechanistic target of rapamycin signaling pathway. Yang et al (23) demonstrated that the inhibition of autophagy could reduce pancreatic cancer stem cell activity and potentiate the tumoricidal effect of gemcitabine. In the present study, the expression of beclin 1, p62 and ATG5 in T24 cells was decreased in a dose-dependent manner following treatment with MMC and increasing 5-Aza-CdR treatment, indicating the reduced autophagy activity. Based on the regulatory role of autophagy in chemosensitivity, it was speculated that 5-Aza-CdR enhanced MMC chemosensitivity of T24 cells partially by suppression of autophagy. Future studies involving autophagy and chemosensitivity are warranted to confirm the conclusions of the present study.

In our previous study, 5-Aza-CdR was revealed to exhibit an inhibitory effect on the proliferation, migration and invasion of T24 bladder cancer cells (8). In the present study, it was demonstrated that 5-Aza-CdR could enhance the cytotoxicity of MMC in T24 cells. This effect may be partially mediated by the suppression of drug resistance- and autophagy-associated proteins. Although the mechanism remains to be clarified, the conclusions of the present study may provide a new therapeutic option to overcome chemoresistance in bladder cancer.

Acknowledgements

The present study was supported by the Science Project of Hengyang City (grant no. 2016KJ34) and the National Natural Science Foundation of China (grant no. 81602241).

References

1 

Chen Y, Yang Y, Liu L, Wang S, Song H and Liu X: Tumor suppressor in lung cancer-1 is a prognostic predictor for the recurrence and progression of non-muscle-invasive bladder cancer. Urol Int. 96:142–147. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Jayaratna IS, Navai N and Dinney CP: Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol. 4:273–282. 2015.PubMed/NCBI

3 

Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al: Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Byun SJ, Kim JH, Oh YK and Kim BH: Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J. 33:294–300. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S, Li J, Wu F, Zhang H, Zhao Z and Ding S: A Potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI

6 

Vasquez JL, Gehl J and Hermann GG: Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: A potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry. 88:127–133. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Gederaas OA, Søgaard CD, Viset T, Bachke S, Bruheim P, Arum CJ and Otterlei M: Increased anticancer efficacy of intravesical mitomycin c therapy when combined with a PCNA targeting peptide. Transl Oncol. 7:812–823. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Zhang H, Qi F, Cao Y, Zu X, Chen M, Li Z and Qi L: 5-Aza-2′-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line. Cancer Biother Radiopharm. 28:343–350. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol. 8:67–113. 1992. View Article : Google Scholar : PubMed/NCBI

10 

Sedláková I, Laco J, Caltová K, Červinka M, Tošner J, Řezáč A and Špaček J: Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer. 25:236–243. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Kovalev AA, Tsvetaeva DA and Grudinskaja TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 35:287–290. 2013.PubMed/NCBI

12 

Roundhill E and Burchill S: Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT. Br J Cancer. 109:195–206. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Yang X, Shen J, Gao Y, Feng Y, Guan Y, Zhang Z, Mankin H, Hornicek FJ and Duan Z: Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 137:2029–2039. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Katagiri H, Nakayama K, Razia S, Nakamura K, Sato E, Ishibashi T, Ishikawa M, Iida K, Ishikawa N, Otsuki Y, et al: Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas. Int J Oncol. 47:2037–2044. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Bartsch G, Jennewein L, Harter PN, Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A, Mittelbronn M and Mani J: Autophagy-associated proteins BAG3 and p62 in testicular cancer. Oncol Rep. 35:1629–1635. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Ge J and Chen Z, Huang J, Chen J, Yuan W, Deng Z and Chen Z: Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS One. 9:e1102932014. View Article : Google Scholar : PubMed/NCBI

17 

Levine B: Cell biology: Autophagy and cancer. Nature. 446:745–747. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Yang Z, Zhao T, Liu H and Zhang L: Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep. 6:193832016. View Article : Google Scholar : PubMed/NCBI

19 

Chang SJ, Ou-Yang F, Tu HP, Lin CH, Huang SH, Kostoro J, Hou MF, Chai CY and Kwan AL: Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24−/low) indicate poor prognosis in triple-negative breast cancer. Hum Pathol. 48:48–55. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Masuda GO, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, et al: Clinicopathological correlations of autophagy-related proteins LC3, Beclin 1 and p62 in gastric cancer. Anticancer Res. 36:129–136. 2016.PubMed/NCBI

21 

Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y and Fan Y: Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Tumour Biol. 37:7371–7381. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther. 9:6421–6431. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Yang MC, Wang HC, Hou YC, Tung HL, Chiu TJ and Shan YS: Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Mol Cancer. 14:1792015. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Zhang HH, Huang B, Cao YH, Li Q and Xu HF: Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells. Oncol Lett 14: 5652-5656, 2017.
APA
Zhang, H., Huang, B., Cao, Y., Li , Q., & Xu, H. (2017). Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells. Oncology Letters, 14, 5652-5656. https://doi.org/10.3892/ol.2017.6853
MLA
Zhang, H., Huang, B., Cao, Y., Li , Q., Xu, H."Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells". Oncology Letters 14.5 (2017): 5652-5656.
Chicago
Zhang, H., Huang, B., Cao, Y., Li , Q., Xu, H."Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells". Oncology Letters 14, no. 5 (2017): 5652-5656. https://doi.org/10.3892/ol.2017.6853
Copy and paste a formatted citation
x
Spandidos Publications style
Zhang HH, Huang B, Cao YH, Li Q and Xu HF: Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells. Oncol Lett 14: 5652-5656, 2017.
APA
Zhang, H., Huang, B., Cao, Y., Li , Q., & Xu, H. (2017). Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells. Oncology Letters, 14, 5652-5656. https://doi.org/10.3892/ol.2017.6853
MLA
Zhang, H., Huang, B., Cao, Y., Li , Q., Xu, H."Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells". Oncology Letters 14.5 (2017): 5652-5656.
Chicago
Zhang, H., Huang, B., Cao, Y., Li , Q., Xu, H."Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells". Oncology Letters 14, no. 5 (2017): 5652-5656. https://doi.org/10.3892/ol.2017.6853
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team